Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FET-PET/MRI for Identifying Small Functional Pituitary Adenomas
NCT07456878Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of O-(2-[18F]fluoroethyl)-L-tyrosine in pituitary adenoma, sponsored by Mayo Clinic. Primary endpoint: Sensitivity of [18F]FET-PET/MRI. Started Jan 2026; status: recruiting.
02
Drugs
O-(2-[18F]fluoroethyl)-L-tyrosine
03
Conditions
pituitary adenoma
Beyond the preview
Go deeper on NCT07456878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07456878.